For research use only. Not for therapeutic Use.
Cefpiramide sodium（Cat No.:I004777）is a broad-spectrum third-generation cephalosporin antibiotic used in the treatment of various bacterial infections. It acts by inhibiting bacterial cell wall synthesis, thereby preventing cell division. Cefpiramide is effective against Gram-positive and Gram-negative bacteria, including strains resistant to other antibiotics. It is commonly used in severe infections, including pneumonia, urinary tract infections, and sepsis. Cefpiramide sodium is administered intravenously or intramuscularly and is considered a potent option for infections caused by multi-drug resistant organisms. Proper dosing and monitoring are essential to avoid resistance development.
| Catalog Number | I004777 |
| CAS Number | 74849-93-7 |
| Molecular Formula | C25H24N8NaO7S2+ |
| Purity | ≥95% |
| Target | Bacterial; Antibiotic |
| Solubility | DMSO: ＞ 39 mg/mL |
| Storage | -20°C |
| IUPAC Name | sodium;(6R,7R)-7-[[(2R)-2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
| InChI | InChI=1S/C25H24N8O7S2.Na/c1-11-7-16(35)15(8-26-11)20(36)27-17(12-3-5-14(34)6-4-12)21(37)28-18-22(38)33-19(24(39)40)13(9-41-23(18)33)10-42-25-29-30-31-32(25)2;/h3-8,17-18,23,34H,9-10H2,1-2H3,(H,26,35)(H,27,36)(H,28,37)(H,39,40);/q;+1/p-1/t17-,18-,23-;/m1./s1 |
| InChIKey | RIWWMGQFMUUYIY-ALLHVENQSA-M |
| SMILES | CC1=CC(=O)C(=CN1)C(=O)N[C@H](C2=CC=C(C=C2)O)C(=O)N[C@H]3[C@@H]4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)[O-].[Na+] |
| Reference | 1:J Drug Target. 2011 Jan;19(1):49-55. doi: 10.3109/10611861003667607. Epub 2010 Mar 5. Tissue distribution and pulmonary targeting studies of cefpiramide sodium-loaded liposomes.Sun Q,Shi M,Shao W,Shi Y,Xi Y,Huang G, PMID: 20205530 DOI: 10.3109/10611861003667607 </br><span>Abstract:</span> The aim of this study was to evaluate the pharmacokinetics (PK), tissue distribution, and the specific drug targeting of cefpiramide sodium-loaded liposomes (CPMS-Lips) compared with cefpiramide sodium solution (CPMS-Sol) in mice. CPMS-Lips were prepared by reverse phase evaporation method. In the PK and biodistribution study, mice received a single intravenous (i.v.) injection of 152 mg/kg of either CPMS-Lips or CPMS-Sol. Plasma and tissues were treated using liquid-liquid extraction and determined using reversed-phase high-performance liquid chromatography (RP-HPLC). The results showed that the CPMS-Lips prepared in this study had an average diameter of 7.146 ± 0.29 μm. In the plasma, the bioavailability (F) and the mean residence times (MRT) of the CPMS-Lips were 2.8- and 4.5-fold larger, respectively, than those of CPMS-Sol. CPMS-Lips also showed a significant difference in the tissue distribution profile in mice when compared with the conventional. The value of the intake rate (r(e)) for the lung was 2.97, which was the highest among the tested tissues. Meanwhile, the ratio of targeting efficiency (Te(liposome)/Te(injection)) of lung to that of other tissues for CPMS-Lips elevated significantly. These showed that CPMS-Lips can improve the bioavailability and biodistribution of CPMS in the lung. In conclusion, the liposome was a promising sustained-release and drug-targeting system for antibiotic drugs. |
